Persistent lipid abnormalities in statin‐treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Diabet. Med. 28, 1343–1351 (2011) Aim To assess the prevalence of persistent lipid abnormalities in statin‐treated patients with diabetes with and without the metabolic syndrome. Methods This was a cross‐sectional study of 22 063 statin‐treated outpatients consecutively recruited by clinicians in Canada and 11 European countries. Patient cardiovascular risk factors, risk level, lipid measurements and lipid‐modifying medication regimens were recorded. Results Of the 20 129 subjects who had documented diabetes and/or metabolic syndrome status, 41% had diabetes (of whom 86.8% also had the metabolic syndrome). Of those with diabetes, 48.1% were not at total cholesterol target compared with 58% of those without diabetes. Amongst those with diabetes, 41.6 and 41.3% of those with and without the metabolic syndrome, respectively, were not at their LDL cholesterol goal relative to 54.2% of those with metabolic syndrome and without diabetes, and 52% of those with neither condition. Twenty per cent of people with diabetes but without the metabolic syndrome were not at the optimal HDL cholesterol level compared with 9% of those with neither condition. Of people with diabetes and the metabolic syndrome, 49.9% were not at optimal triglyceride level relative to 13.5% of people with neither diabetes nor the metabolic syndrome. Simvastatin was the most commonly prescribed statin (> 45%) and the most common statin potency was 20–40 mg/day (simvastatin equivalent). Approximately 14% of patients were taking ezetimibe alone or in combination with a statin. Conclusions Despite evidence supporting the benefits of lipid modification and international guideline recommendations, statin‐treated patients with diabetes had a high prevalence of persistent lipid abnormalities. There is frequently room to optimize therapy through statin dose up‐titration and/or addition of other lipid‐modifying therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475
Scientific evidence underlying the ACC/AHA clinical practice guidelines.
Tricoci, P. (2009) · JAMA · doi:10.1001/jama.2009.205 · Cited by 908
Kotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., & Keil, U. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60330-5 · Cited by 833
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Cited by
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Lee, J. S., Chang, P.-Y., Zhang, Y., Kizer, J. R., Best, L. G., & Howard, B. V. (2017) · Diabetes Care · doi:10.2337/dc16-1958 · Cited by 325
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
Leiter, L. A., Teoh, H., Kallend, D., Wright, R. S., Landmesser, U., Wijngaard, P. L. J., Kastelein, J. J. P., & Ray, K. K. (2019) · Diabetes Care · doi:10.2337/dc18-1491 · Cited by 117
Self-citationDemystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Metadata
- Authors
- Leiter, L. A., Lundman, P., da Silva, P. M., Drexel, H., Jünger, C., Gitt, A. K., & on behalf of the DYSIS investigators
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2011-10-17
- Volume
- 28
- Issue
- 11
- Pages
- 1343-1351
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W1918902660
- Cited by
- 95
- References
- 8
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Persistent lipid abnormalities in statin‐treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. https://app.cochat.ai/papers/10.1111/j.1464-5491.2011.03360.x
- The paper
- Leiter, L. A., Lundman, P., da Silva, P. M., Drexel, H., Jünger, C., Gitt, A. K., & on behalf of the DYSIS investigators. (2011). Persistent lipid abnormalities in statin‐treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2011.03360.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.